Balcom Alexandra 4
4 · Nuvalent, Inc. · Filed May 5, 2026
Research Summary
AI-generated summary of this filing
Nuvalent (NUVL) CFO Alexandra Balcom Sells Shares After Option Exercise
What Happened
Alexandra Balcom, Chief Financial Officer of Nuvalent, exercised fully vested stock options for a total of 11,430 shares (7,159 shares at $1.08 and 4,271 shares at $6.89), paying approximately $37,159 to exercise. On the same day (May 1, 2026) she sold all 11,430 shares in open-market transactions for aggregate proceeds of about $1,131,600 (three weighted-average sale prices: $98.42, $99.29 and $99.97).
Key Details
- Transaction date: May 1, 2026; Form 4 filed May 5, 2026 (filed within the normal two-business-day window for a May 1 transaction).
- Option exercises: 7,159 shares @ $1.08 (cost $7,732) and 4,271 shares @ $6.89 (cost $29,427). Footnote: the options underlying these shares are fully vested.
- Market sales: 3,872 shares @ $98.42 (WAP), 7,434 shares @ $99.29 (WAP), and 124 shares @ $99.97 (WAP); total proceeds ≈ $1,131,600. The sale prices were reported as weighted averages with ranges: $97.84–$98.83; $98.85–$99.80; and $99.86–$100.36.
- Plan/authorization: Sales were effected under a Rule 10b5-1 trading plan adopted December 23, 2025.
- Shares owned after the transaction: Not disclosed in this Form 4.
Context
- This was effectively a cashless exercise: Balcom exercised options and the resulting shares were sold the same day (all 11,430 shares sold), which is a routine way for insiders to convert option value to cash and is not necessarily a signal about company prospects.
- The presence of a 10b5-1 plan means the trades were pre-scheduled, reducing the likelihood they were timed based on nonpublic information.
Insider Transaction Report
Form 4
Nuvalent, Inc.NUVL
Balcom Alexandra
Chief Financial Officer
Transactions
- Exercise/Conversion
Class A Common Stock
[F1]2026-05-01$1.08/sh+7,159$7,732→ 92,692 total - Exercise/Conversion
Class A Common Stock
[F1]2026-05-01$6.89/sh+4,271$29,427→ 96,963 total - Sale
Class A Common Stock
[F1][F2]2026-05-01$98.42/sh−3,872$381,082→ 93,091 total - Sale
Class A Common Stock
[F1][F3]2026-05-01$99.29/sh−7,434$738,122→ 85,657 total - Sale
Class A Common Stock
[F1][F4]2026-05-01$99.97/sh−124$12,396→ 85,533 total - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F5]2026-05-01−7,159→ 131,637 totalExercise: $1.08Exp: 2031-02-16→ Class A Common Stock (7,159 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F5]2026-05-01−4,271→ 24,830 totalExercise: $6.89Exp: 2031-04-29→ Class A Common Stock (4,271 underlying)
Footnotes (5)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2025.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.84 to $98.83, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4) of this Form 4.
- [F3]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.85 to $99.80, inclusive.
- [F4]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.86 to $100.36, inclusive.
- [F5]The shares underlying this option are fully vested.
Signature
/s/ Nathan N. McConarty, attorney-in-fact|2026-05-05